PhageTech, Inc.'s proprietary technology consists of engineered bacteriophages incorporated into bioconducting sensors, originally developed and patented by the University of California, Irvine, and licensed to PhageTech, Inc.
PhageTech, Inc.’s bioconducting materials are antibody-free, reagent-free, label-free, and nearly instantaneous. The result is a biologically active and electrically passive multi-channel biosensor, creating a quantifiable signal when in contact with specific disease biomarkers. The biosensor is capable of performing multiple simultaneous assays without complex sample processing. A fluid-in and data-out model eliminates the need for any special training, lab equipment, or capital equipment. Each biosensor can be read by a self-powered handheld reader, with patient results instantly displayed using a smartphone app and securely transported to the cloud.